Your browser doesn't support javascript.
loading
Chronic diarrhoea, weight loss and a positive anti-tissue transglutaminase antibody: A case report of olmesartan-induced enteropathy.
Sheppard, Rachel; Evanson, Benjamin; Campbell, Iona; Shand, Alan.
Afiliação
  • Sheppard R; NHS Lothian, Edinburgh, UK.
  • Evanson B; NHS Lothian, Edinburgh, UK ben.evanson@nhs.scot.
  • Campbell I; NHS Lothian, Edinburgh, UK.
  • Shand A; Gastroenterology Unit, NHS Lothian, Edinburgh, UK.
BMJ Case Rep ; 17(5)2024 May 06.
Article em En | MEDLINE | ID: mdl-38719261
ABSTRACT
Olmesartan is an angiotensin II receptor blocker licensed for the treatment of hypertension. It can cause a sprue-like enteropathy (SLE), characterised by chronic diarrhoea, weight loss and villous atrophy. Transiently raised anti-tissue transglutaminase (ATTG) antibody has also been rarely reported in the literature.We describe the case of a woman in her mid-50s, who presented with a history of intermittent loose stools over 1 year, associated with significant weight loss. She had two marginally raised serum ATTG antibody tests during her work-up.After extensive investigations, she was diagnosed with olmesartan-induced enteropathy. On subsequent follow-up, her symptoms had resolved with cessation of her olmesartan therapy.This case adds to existing literature, highlighting the importance of considering olmesartan as a possible differential diagnosis for SLE. It also reports the presence of a raised ATTG antibody which is infrequently reported in this context.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tetrazóis / Redução de Peso / Transglutaminases / Diarreia / Imidazóis Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tetrazóis / Redução de Peso / Transglutaminases / Diarreia / Imidazóis Idioma: En Ano de publicação: 2024 Tipo de documento: Article